In its latest financial report, Monte Rosa Therapeutics has announced a significant partnership with Novartis, alongside progress in its pipeline of drug candidates. The partnership involves a global ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

DelveInsight's Dry Eye Disease Treatment Market Insights report provides the current and forecast market analysis, individual ...

LSD is a relatively new drug, compared to many others. And its history has been influenced by some unlikely groups.

TD Cowen analyst Steve Scala maintained a Hold rating on Novartis (NVS – Research Report) today. The company’s shares closed ...

Minister of State for Digital Dara Calleary TD Officiated At ‘How Ireland can be the Centre of Artificial Intelligence (AI) ...

European markets closed lower Tuesday as traders in the region continued to digest the latest slew of earnings reports.

Novartis AG’s best-selling drug and a key new cancer medicine posted disappointing sales last quarter, even as the Swiss drugmaker lifted profit guidance for a third straight quarter. Sales of heart ...

Novartis raised its 2024 earnings guidance for the third time on Tuesday, buoyed by wider use of its prescription drugs, but ...

The Swiss pharma is paying $150 million upfront to gain rights to Monte Rosa’s VAV1-targeting molecular glue degraders, led ...